PIPE-791 enters clinical phase: Pipeline Therapeutics’ precision approach to neuroinflammation treatment

PIPE-791 enters clinical phase: Pipeline Therapeutics’ precision approach to neuroinflammation treatment

Pipeline Therapeutics, a clinical-stage biopharmaceutical firm specializing in precision neuroregeneration, has announced the initiation of dosing for the Phase 1 clinical trial of PIPE-791 in healthy volunteers. The novel small molecule antagonist targets the lysophosphatidic acid 1 receptor (LPA1), setting the stage for a new era in treating CNS indications. Carmine Stengone, President and CEO […]

Novartis acquires biotech firm DTx Pharma to gain access to FALCON platform

Novartis acquires biotech firm DTx Pharma to gain access to FALCON platform

Swiss pharmaceutical giant Novartis has acquired DTx Pharma, a preclinical stage biotechnology company based in California renowned for its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON) platform, which addresses the delivery challenges of oligonucleotide therapeutics. This acquisition, including the revolutionary FALCON platform, will enhance the delivery of small interfering RNA (siRNA) therapeutics to tissues beyond the […]

Lupin subsidiary MedQuímica buys rights to nine drugs from Bausch Health

Lupin subsidiary MedQuímica buys rights to nine drugs from Bausch Health

Lupin Limited said that MedQuímica Indústria Farmacêutica, its 100% subsidiary in Brazil, has agreed to acquire all rights to nine drugs from Bausch Health Companies’ subsidiary BL Indústria Ótica. The financial terms of the deal were not disclosed. Through the deal, MedQuímica will gain rights to the three central nervous system drugs — Limbitrol, Melleril, […]

Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals

Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals

Tenzing Acquisition has agreed to acquire Reviva Pharmaceuticals, a California-based clinical-stage pharma company, focused on developing therapies for addressing unmet medical needs in the areas of central nervous system, metabolic, cardiovascular, and inflammatory diseases. According to the British Virgin Islands-incorporated special purpose acquisition company, the equity value of the combined company post its merger with […]

US biotech company Viela Bio bags Uplizna FDA approval for NMOSD

US biotech company Viela Bio bags Uplizna FDA approval for NMOSD

Uplizna FDA approval : US biotech company Viela Bio has secured approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease of the central nervous system (CNS). The approval of Uplizna is for neuromyelitis optica spectrum […]

Alkermes to acquire Boston-based neuroscience company Rodin Therapeutics

Alkermes to acquire Boston-based neuroscience company Rodin Therapeutics

Alkermes acquisition of Rodin Therapeutics : Irish biopharma company Alkermes has agreed to acquire Boston-based neuroscience company Rodin Therapeutics in a deal worth up to $950 million as per the latest pharma acquisition news. Rodin Therapeutics is engaged in developing novel, small molecules for the treatment of synaptopathies. Alkermes acquisition of Rodin Therapeutics is said […]

LAVENDER phase 3 clinical trial launched for trofinetide in Rett syndrome by Acadia Pharmaceuticals

LAVENDER phase 3 clinical trial launched for trofinetide in Rett syndrome by Acadia Pharmaceuticals

US biopharma company Acadia Pharmaceuticals has launched the LAVENDER phase 3 clinical trial to evaluate the efficacy and safety of trofinetide for the treatment of Rett syndrome in girls and young women. Rett syndrome is considered to be a serious and rare neurodevelopmental congenital disorder related to the central nervous system (CNS). Symptoms of Rett […]

Lilly bags Reyvow FDA approval for acute treatment of migraine

Lilly bags Reyvow FDA approval for acute treatment of migraine

Reyvow FDA approval : Eli Lilly and Company (Lilly) has bagged approval from the US Food and Drug Administration (FDA) for Reyvow (lasmiditan) for the acute treatment of migraine, irrespective of aura (a sensory phenomenon or visual disturbance), in adults. The oral treatment, which has been designed to bind to 5-HT1F receptors with high affinity, […]